ASCO 2019 – Lenalidomide reduces risk that smoldering myeloma will progress to myeloma in high risk patientsConferences, Myeloma31 May 2019
Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European CommissionAccess, Myeloma23 May 2019
Call to action for Central and Eastern European (CEE) members – join MPE CEE workgroup on accessAccess, MPE6 May 2019
Results of MPE members participation in EMA survey on bortezomibMPE, Myeloma, Patient evidence3 May 2019
MPE will hold a webinar on ASH 2018 highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, Myeloma16 January 2019
